The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations
- PMID: 21411785
- DOI: 10.1309/AJCPP5R2ZJZKCLWN
The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations
Abstract
Two promising ancillary tests used in the diagnosis of mesothelioma include GLUT-1 immunohistochemical analysis and fluorescence in situ hybridization (FISH) testing for the p16 deletion. This study compared the diagnostic usefulness of p16 FISH and GLUT-1 immunohistochemical analysis in the diagnosis of mesothelial proliferations in 158 cases with a diagnosis of benign (45.4%), atypical (10.4%), or malignant/mesothelioma (44.2%). Of the 70 benign cases, none had a deletion of p16 and 5 cases (7%) were positive for GLUT-1. Of the 68 mesotheliomas, 40 (59%) had a deletion of p16 (sensitivity, 59%; specificity, 100%) and 27 (40%) were positive for GLUT-1 (sensitivity, 40%; specificity, 93%). GLUT-1 showed lower sensitivity in pleural (56% vs 70%) and peritoneal (29% vs 51%) mesotheliomas (P = .004). Our results demonstrate that p16 FISH is a more sensitive and specific test than GLUT-1 immunohistochemical analysis and can be a more reliable ancillary tool to support the diagnosis of mesothelioma.
Similar articles
-
9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.Pathol Int. 2010 May;60(5):395-9. doi: 10.1111/j.1440-1827.2010.02534.x. Pathol Int. 2010. PMID: 20518890
-
Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.Mod Pathol. 2008 Jun;21(6):742-7. doi: 10.1038/modpathol.2008.45. Epub 2008 Mar 7. Mod Pathol. 2008. PMID: 18327208
-
p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.Am J Surg Pathol. 2014 May;38(5):681-8. doi: 10.1097/PAS.0000000000000176. Am J Surg Pathol. 2014. PMID: 24503757
-
Implications of P16/CDKN2A deletion in pleural mesotheliomas.Lung Cancer. 2005 Jul;49 Suppl 1:S95-8. doi: 10.1016/j.lungcan.2005.03.017. Epub 2005 Apr 14. Lung Cancer. 2005. PMID: 15950811 Review.
-
The separation of benign and malignant mesothelial proliferations.Arch Pathol Lab Med. 2012 Oct;136(10):1217-26. doi: 10.5858/arpa.2012-0112-RA. Arch Pathol Lab Med. 2012. PMID: 23020727 Review.
Cited by
-
Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.Med Oncol. 2014 Dec;31(12):303. doi: 10.1007/s12032-014-0303-2. Epub 2014 Oct 31. Med Oncol. 2014. PMID: 25358615
-
CDKN2A and MTAP Are Useful Biomarkers Detectable by Droplet Digital PCR in Malignant Pleural Mesothelioma: A Potential Alternative Method in Diagnosis Compared to Fluorescence In Situ Hybridisation.Front Oncol. 2020 Nov 13;10:579327. doi: 10.3389/fonc.2020.579327. eCollection 2020. Front Oncol. 2020. PMID: 33304846 Free PMC article.
-
[Mesothelial proliferation in rectal cancer].Pathologe. 2014 Feb;35(1):88-92. doi: 10.1007/s00292-013-1880-0. Pathologe. 2014. PMID: 24496993 German.
-
A gene-expression-based test can outperform bap1 and p16 analyses in the differential diagnosis of pleural mesothelial proliferations.Oncol Lett. 2020 Jan;19(1):1060-1065. doi: 10.3892/ol.2019.11174. Epub 2019 Dec 2. Oncol Lett. 2020. PMID: 31897219 Free PMC article.
-
GFPT2: A novel biomarker in mesothelioma for diagnosis and prognosis and its molecular mechanism in malignant progression.Br J Cancer. 2024 Nov;131(9):1529-1542. doi: 10.1038/s41416-024-02830-4. Epub 2024 Sep 24. Br J Cancer. 2024. PMID: 39317702
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous